Exact Sciences Corp (EXAS) Posts Q2 Loss of 13c/Sh., Wider than Views
Exact Sciences Corp (NASDAQ: EXAS) reported Q2 loss of ($0.13), $0.03 worse than the analyst estimate of ($0.10). Revenue for the quarter came in at $1 million versus the consensus estimate of $1.02 million.